Networks of Centres of Excellence of Canada
Government of Canada

Common menu bar links

Nanomedicines Innovation Network - NMIN

$18.5 million for 2019-25
About   |   News
Nanomedicines Innovation Network

University of British Columbia, Vancouver, British Columbia

Chief Executive Officer and Scientific Director
Pieter Cullis Pieter Cullis

Board Chair
Don EnnsDon Enns
Vice-President and Head of Global Drug Delivery, Evonik Industries

Advancing nanomedicines to defeat disease

The opportunity

Nanomedicines or “smart” medicines that employ various forms of nanotechnology, are poised to have a revolutionary impact on drug development. Nanomedicines will deliver drugs, such as anticancer drugs, more specifically to disease sites to dramatically improve efficacy, to reduce toxicity and also to enable gene therapies employing RNA and DNA with the potential to treat most human diseases. Further, diagnostics and imaging agents based on nanotechnology will allow us to detect disease earlier and monitor the effectiveness of therapy more accurately.

How NMIN is seizing the opportunity

The NanoMedicines Innovation Network (NMIN) establishes and mobilizes a network drawn from academia, industry and other not-for-profit research enterprises to maintain and improve Canada’s position as a global leader in developing next generation nanomedicines. NMIN develops novel therapeutics to cure high burden human diseases, new diagnostics to detect disease more precisely and commercializes these products to bring health and economic benefits to Canadians. In addition, NMIN trains the skilled workforce required by the growing nanomedicines industry.

Among the expected results

  • Develop and license to partner companies at least 7 new nanomedicines to improve cancer treatment and to treat inherited diseases.
  • Develop and license to partner companies at least 3 new diagnostics based on nanotechnology that enable more precise disease detection and treatment.
  • Create at least 75 new highly skilled jobs, resulting from the expansion of existing partner companies and the formation of at least 10 new companies.
  • Train at least 350 highly-qualified personnel (HQP) to meet the urgent needs of the Canadian nanomedicines industry and to ensure our workforce is globally competitive.

Connect with NMIN